Myriad Completes Spin Off of Pharma Business

Myriad Genetics' shareholders received shares in the pharma spin off. The firm also said it had retained the rights to claim $400 million in tax deductions.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.